BioVie (NASDAQ: BIVI) CEO entity awarded 665,300 stock options equity

Rhea-AI Filing Summary

BioVie Inc. reported an insider equity award connected to its President & CEO, Cuong V Do. On January 5, 2026, Do & Rickles Investments LLC, an entity associated with him, was granted a stock option to buy 665,300 shares of BioVie common stock at an exercise price of $1.31 per share. The option was reported as an indirect holding.

According to the vesting terms, 55% of the options vested on January 5, 2026, with the remaining balance vesting in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029. The filing shows a grant price of $0 for the derivative security itself, which reflects that this was an option award rather than an open‑market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider DO CUONG V

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	665,300	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 665,300 shares (Indirect, See Footnote)

Footnotes (1)

1. 55% of the options vested on January 5, 2026 and the remainder of the options vest in three equal installments on January 5, 2027, January 5, 2028 and January 5, 2029. Securities are held in the name of Do & Rickles Investments LLC.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DO CUONG V

(Last) (First) (Middle)

C/O BIOVIE INC.

680 W NYE LANE STE 201

(Street)

CARSON CITY NV 89703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOVIE INC. [ BIVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.31	01/05/2026		A		665,300		(1)	01/05/2036	Common Stock	665,300	$0	665,300	I	See Footnote(2)

Explanation of Responses:

1. 55% of the options vested on January 5, 2026 and the remainder of the options vest in three equal installments on January 5, 2027, January 5, 2028 and January 5, 2029.

2. Securities are held in the name of Do & Rickles Investments LLC.

	/s/ Joanne Wendy Kim, attorney-in-fact for Cuong V Do	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BioVie (BIVI) disclose in this Form 4?

The filing shows a grant of a stock option for 665,300 shares of BioVie common stock at an exercise price of $1.31 per share, reported as an indirect holding.

Who is the reporting person in the BioVie (BIVI) Form 4 and what is their role?

The reporting person is Cuong V Do, who serves as a Director and as President & CEO of BioVie Inc.

How are the 665,300 BioVie (BIVI) stock options held?

The options are held indirectly through Do & Rickles Investments LLC, as disclosed in a footnote stating the securities are in that entity's name.

What is the vesting schedule for the BioVie (BIVI) stock options granted on January 5, 2026?

55% of the options vested on January 5, 2026. The remaining options vest in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029.

What price did the insider-related entity pay for the BioVie (BIVI) stock option award?

The filing reports a transaction price of $0 for the derivative security and an exercise price of $1.31 per share for the underlying BioVie common stock.

How many BioVie (BIVI) derivative securities does the insider-related entity hold after this transaction?

Following the reported grant, the entity holds 665,300 derivative securities (stock options) linked to BioVie common stock.